$AMPE nothing to see here ... keep buying As of and for the six months ended June 30, 2020, the Company had cash and cash equivalents of $4.8 million and a net loss of $7.9 million. As a clinical stage biopharmaceutical company, the Company has not generated any operating revenues or profits to date. These existing and projected on-going factors continue to raise substantial doubt about the Company’s ability to continue as a going concern